This article is more than 5 years old. Information may no longer be current.

Allergan, Sanwa Kagaku to develop Posurdex in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — An extended-release implant that delivers a corticosteroid to targeted disease sites for the treatment of macular edema will be jointly developed and marketed in Japan by Allergan and Sanwa Kagaku Kenkyusho Co., according to a press release.

Under terms of the agreement, Sanwa will be responsible for the development and commercialization of Posurdex (dexamethasone) in Japan and will incur associated costs, the release said. Allergan will collect a royalty on net sales; Sanwa will make development and commercialization milestone payments and reimburse Allergan for certain expenses associated with clinical trials outside Japan.

Allergan is conducting two phase 3 trials worldwide with Posurdex, focusing on the implant as a treatment for macular edema associated with diabetes and other conditions. Sanwa will begin phase 1 and 2 development in Japan some time this year, according to the press release.